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It is present at the interface of the glomerular basement membrane and interstitial matrix and its levels have been reported elevated in glomeruli of patients with glomerular diseases and in the mesangium of diabetic patients. During deposition of COL VI, a fragment is released, namely endotrophin (ETP). Endotrophin (ETP), has shown profibrotic potential. We investigated the prognostic potential of COL VI formation and ETP for CKD progression by measuring baseline levels in urine and plasma from patients with DN. METHODS: COL VI formation and ETP were measured using a novel enzyme-linked immunosorbent assay targeting the C-terminal end of the a3 chain of COL VI (Pro-C6). Patients with type 1 or 2 diabetes receiving renin angiotensin system inhibitors were included if they had serum creatinine concentrations between 1.3 to 3.5 mg/dl (or estimated glomerular filtration rate (eGFR) between 20 to 60 mL/min/1.73 m 2 ) or a 24-hour urine protein/creatinine ratio (PCR) 800 mg/g. Paired urine and plasma baseline samples from 99 DN patients who participated in a one year therapeutic clinical study (NCT01113801). Urinary Pro-C6 was normalized to urinary creatinine. The outcome of interest was change of eGFR (calculated with the MDRD formula) from baseline to 9 and 12 months. RESULTS: Levels of Pro-C6 in both plasma and urine correlated with eGFR at baseline, 9 month, and 12 months (all p<0.0001). Moreover, urinary Pro-C6 correlated with change in eGFR at 9 and 12 months (both p<0.01). Whereas levels of Pro-C6 in urine correlated significantly with PCR (p<0.0001) no correlation between plasma Pro-C6 and PCR was observed (p=0.99). Urinary Pro-C6 was independently associated with decrease in eGFR at both 9 months (r=-0.335, p<0.01) and 12 months (r=-0.358, p<0.01) even after adjustment for eGFR and PCR. When patients were divided into quartiles based on their rate of eGFR change over 12 months, urinary Pro-C6 adjusted for baseline eGFR and PCR was able to separate the fastest progressing patients with an AUC of 0.732 (p<0.001). CONCLUSIONS: We found a significant association between the Pro-C6 marker of COL VI formation and CKD progression in patients with DN, independent of baseline eGFR and proteinuria. Because the Pro-C6 assay cross-reacts with the matrikine endotrophin, these results might suggest a role for endotrophin in disease progression. 
INTRODUCTION AND AIMS:
Patients with chronic kidney disease (CKD) have increased risk of progressing to end-stage renal disease (ESRD) and a high mortality rate. One of the major underlying causes of progression of renal failure is renal fibrosis, which is caused by dysregulated extracellular matrix (ECM) remodeling. The laminin c1 (LAMC1) chain is a constituent of the laminin types present in the glomerular basement membrane (GBM), and its turnover may be altered in CKD. Fragments of LAMC1 could quantify GBM turnover in human CKD and reflect pathological tissue changes. We developed an immunoassay targeting LG1M, a neo-epitope of LAMC1 generated by matrix metalloproteinases (MMPs). We then measured
LG1M levels in serum and urine from a large prospective cohort of patients with highrisk CKD. METHODS: A novel immunoassay targeting a specific MMP-9-generated neo-epitope fragment of LAMC1 (LG1M) was used to measure the fragment levels in urine and serum from 492 patients from the Renal Impairment in Secondary Care (RIISC) study, a prospective cohort of patients with high-risk CKD. Patients were monitored for a median follow-up time of 2.5 years. Progression of CKD was defined as a decline in eGFR of more than 30%, or starting renal replacement therapy as a definition of endstage-renal disease (ESRD) within 12 months. Associations between LG1M levels in both serum and urine for progression of CKD were assessed by a multivariable logistic regression model with forward selection, while adverse outcomes were assessed by Kaplan-Meier and Cox regression analysis. RESULTS: Forty-six patients (11%) of 411 patients who were alive and under followup at 12 months had progressed. During the study 102 patients developed ESRD and 65 patients died. Both urinary and serum levels of LG1M showed an inverse linear correlation with baseline eGFR (Spearman's correlation coefficient r=-0.43, p<0.0001 and r=-0.17, p=0.0002, respectively). Serum but not urinary LG1M levels were significantly associated with progression of CKD within 12 months (p<0.01), but were not included in the final model for prediction of whether the patients developed ESRD. Urinary LG1M levels were significantly associated with death; patients in the highest LG1M tertile were 4.5 (p<0.0001) times more likely to die than patients in the first tertile. Urinary LG1M levels were included in the final model for prediction of mortality (HR 1.25, 95% CI 1.04-1.51, p=0.02). CONCLUSIONS: The novel biomarker LG1M reflecting glomerular basement membrane remodeling is associated with disease progression, development of ESRD, and mortality in high-risk CKD patients.
